日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study

LEANORA 研究:利博西尼在转移性乳腺癌黑人患者中的药代动力学和药物基因组学

Schlam, Ilana; Smith, D Max; Peer, Cody; Sissung, Tristan; Schmidt, Keith T; Tan, Ming; Chitalia, Ami; Bishopric, Nanette H; Steinberg, Seth; Choo-Wosoba, Hyoyoung; Napoli, Giulia; Gallagher, Christopher; Ashai, Nadia; Whitaker, Kristen; Mainor, Candace; Tiwari, Shruti; Swanson, Nicole; Malloy, Stacy; Isaacs, Claudine; Figg, William Douglas; Swain, Sandra M

DPYD Testing: Time to Put Patient Safety First

DPYD 检测:是时候把患者安全放在首位了

Baker, Sharyn D; Bates, Susan E; Brooks, Gabriel A; Dahut, William L; Diasio, Robert B; El-Deiry, Wafik S; Evans, William E; Figg, William D; Hertz, Dan L; Hicks, J Kevin; Kamath, Suneel; Kasi, Pashtoon Murtaza; Knepper, Todd C; McLeod, Howard L; O'Donnell, Peter H; Relling, Mary V; Rudek, Michelle A; Sissung, Tristan M; Smith, D Max; Sparreboom, Alex; Swain, Sandra M; Walko, Christine M

GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy

接受雄激素剥夺疗法治疗的前列腺癌患者的GNRH2多态性

Sissung, Tristan M; Lochrin, Sarah; Liu, Tyler; Schmidt, Keith; Strope, Jonathan; Risdon, Emily; Choo-Wosoba, Hyoyoung; Venzon, David J; Lassoued, Wiem; Sater, Houssein A; Walter-Rodriguez, Beatriz; Price, Douglas K; Figg, William D

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

肿瘤I期临床试验中的药物基因组学检测:建设性批评是必要的

Sissung, Tristan M; Figg, William D

Commentary: Electronic Nicotine Delivery Systems: Seeing Through the Clouds

评论:电子尼古丁输送系统:拨开迷雾

Sissung, Tristan M; Figg, William D

Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome

抗Jo-1抗合成酶综合征患者对放化疗的毒性增强

Valle, Luca; Katz, James; Duffy, Austin; Hueman, Matthew; Wang, Hao-Wei; Hughes, Marybeth; Sissung, Tristan; Figg, William; Citrin, Deborah

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

佐替拉西尼联合替莫唑胺治疗复发性高级别星形细胞瘤患者的 I 期研究

Wu, Jing; Yuan, Ying; Long Priel, Debra A; Fink, Danielle; Peer, Cody J; Sissung, Tristan M; Su, Yu-Ting; Pang, Ying; Yu, Guangyang; Butler, Madison K; Mendoza, Tito R; Vera, Elizabeth; Ahmad, Salman; Bryla, Christine; Lindsley, Matthew; Grajkowska, Ewa; Mentges, Kelly; Boris, Lisa; Antony, Ramya; Garren, Nancy; Siegel, Christine; Lollo, Nicole; Cordova, Christine; Aboud, Orwa; Theeler, Brett J; Burton, Eric M; Penas-Prado, Marta; Leeper, Heather; Gonzales, Javier; Armstrong, Terri S; Calvo, Katherine R; Figg, William D; Kuhns, Douglas B; Gallin, John I; Gilbert, Mark R

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

NLG207(以前称为 CRLX101)与恩杂鲁胺联合用于临床前前列腺癌模型的抗肿瘤活性

Keith T Schmidt, Cindy H Chau, Jonathan D Strope, Alwin D R Huitema, Tristan M Sissung, Douglas K Price, William D Figg

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors

索拉非尼和伊立替康治疗复发或难治性实体瘤患儿的I期研究

Meany, Holly J; Widemann, Brigitte C; Hinds, Pamela S; Bagatell, Rochelle; Shusterman, Suzanne; Stern, Emily; Jayaprakash, Nalini; Peer, Cody J; Figg, William D; Hall, O Morgan; Sissung, Tristan M; Kim, Aerang; Fox, Elizabeth; London, Wendy B; Rodriguez-Galindo, Carlos; Minturn, Jane E; Dome, Jeffrey S

Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD

病例报告:接受 FOLFOX 治疗且携带 DPYD 罕见等位基因变异的非裔美国患者出现严重毒性

Tristan M Sissung, Lisa Cordes, Cody J Peer, Shruti Gandhy, Jason Redman, Julius Strauss, William D Figg